Last month, we got the chance to discuss DCIS with three doctors from NYU Cancer Center: Dr. Deborah Axelrod, Dr. Julia Smith, and Dr. David Kleinberg.
Last month, we got the chance to discuss DCIS with three doctors from NYU Cancer Center: Dr. Deborah Axelrod, Dr. Julia Smith, and Dr. David Kleinberg.
They explain what DCIS is, discuss public trials and future directions for DCIS, and address some current controversies around the diagnosis.
Listen to the talk here:
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.